The deal centers around Poiesis’ dual-balloon catheter, the Duette system. Under the terms, HR Pharmaceuticals has exclusive commercialization rights to Duette in North America. The deal expands HR Pharmaceuticals’ growing urological portfolio across the continuum of care.
HR Pharmaceuticals aims to address adverse events associated with Foley catheterization.
“The dual-balloon catheter has demonstrated significant benefits compared to traditional Foley catheters, leading to better patient outcomes. Specifically, we see a great opportunity for patients requiring indwelling catheterization greater than five days,” said Colby Wiesman, president of HR Pharmaceuticals. “This product will become an important part of our broader urology strategy over the next 12 months.”
HR Pharmaceuticals plans to begin processing North American orders for Duette on Jan. 2, 2024. Distributors including Cardinal Health, Medline and Owens & Minor offer the system.
“The dual-balloon catheter technology, a brainchild of my father, Dr. Bruce Wiita, a practicing urologist and decorated Vietnam veteran, was born out of a genuine desire to improve the quality of life for patients enduring prolonged catheterization and to alleviate the strains it places on the healthcare system,” said Gregory Wiita, CEO and founder at Poiesis Medical. “We are excited about this new chapter with HR Pharmaceuticals and the potential of the technology to make a meaningful impact in patient care.”
